RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All FDA (CDER) updates
FDA (CDER)
GUIDANCE DRAFT
Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling
Published: 9/2/2026Detected: 9/4/2026

Summary preview

Clarifies how pharmacokinetic studies in patients with impaired hepatic function should be designed and analyzed to support labeling recommendations, with an emphasis on translating PK findings into dosing adjustments.

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
clinical
safety
labeling
gastroenterology
#pharmacokinetics
#hepatic impairment
#dose adjustment
#labeling
#Child-Pugh

Official Source Document
Source Verified

Access the original document directly from FDA CDER.

View Official Document

More from FDA (CDER)

  • E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers (R1): Guidance for Industry10/30/2026
  • Submitting Clinical Trial Data to Evaluate the Ability to Operate a Motor Vehicle10/20/2026
  • Regulatory Considerations for Prescription Drug Use-Related Software10/20/2026
  • Safety Reporting Requirements for INDs and BA/BE Studies: Guidance for Industry and Investigators10/19/2026
  • Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers10/9/2026

Get FDA (CDER) alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service
  • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.